What is the recommended dosage and administration protocol for Amiodarone (antiarrhythmic medication) intravenous (IV) perfusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amiodarone IV Perfusion Protocol

The standard IV amiodarone protocol consists of a 150 mg bolus over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours, with a maximum total dose of 2.2 g over 24 hours. 1

Loading Dose Administration

Initial Bolus:

  • 150 mg IV over 10 minutes for rapid loading 2, 3, 1
  • Mix in 100 mL D5W to minimize hypotension 1
  • Must use volumetric infusion pump, not drop counters (which can underdose by up to 30%) 1

Early Maintenance Phase:

  • 1 mg/min for 6 hours (total 360 mg) 2, 3, 1
  • This phase provides continued loading while minimizing hemodynamic effects 1

Late Maintenance Phase:

  • 0.5 mg/min for 18 hours (total 540 mg) 2, 3, 1
  • Combined with initial bolus and early maintenance, total 24-hour dose = 1050 mg 1

Supplemental Dosing for Breakthrough Arrhythmias

  • 150 mg supplemental bolus over 10 minutes for breakthrough VF or hemodynamically unstable VT 1
  • Mix in 100 mL D5W 1
  • Can repeat as needed, but do not exceed 2.2 g total in 24 hours 3, 1
  • Mean daily doses above 2100 mg associated with increased hypotension risk 1

Critical Administration Requirements

Infusion Setup:

  • Use central venous catheter whenever possible 1
  • For peripheral access: concentrations ≤2 mg/mL only (concentrations >3 mg/mL cause high phlebitis rates) 1
  • Central line required for concentrations >2 mg/mL 1
  • Must use glass or polyolefin bottles for infusions >2 hours 1
  • Use in-line filter during administration 1

Concentration Limits:

  • ≤2 mg/mL for peripheral IV (infusions >1 hour) 1
  • Up to 6 mg/mL via central line 1
  • Higher concentrations and faster rates than recommended have caused hepatocellular necrosis, acute renal failure, and death 1

Mandatory Monitoring During Infusion

Continuous monitoring required for: 2, 3

  • Cardiac rhythm (continuous ECG) 2, 3
  • Blood pressure (frequent measurements) 3
  • Heart rate 2

Watch for critical adverse effects:

  • Hypotension (most common serious effect, occurred in 23% of patients in one study) 4
  • Bradycardia (occurred in 11% in one study) 4
  • AV block 2, 1
  • Defibrillator must be immediately available 2

Special Clinical Contexts

Life-Threatening Ventricular Arrhythmias:

  • Use standard protocol above for VF or hemodynamically unstable VT 2, 1
  • Appropriate only after defibrillation and epinephrine in cardiac arrest 2

Atrial Fibrillation Cardioversion:

  • Same dosing protocol as above 2, 3
  • Conversion typically occurs after 6-8 hours, often requiring ≥1000 mg total dose 3
  • Conversion rates: 34-69% with bolus-only, 55-95% with bolus plus continuous infusion 3

Patients with Structural Heart Disease:

  • Amiodarone is particularly valuable when Class IC agents contraindicated 3
  • Use with caution in moderate-severe LV dysfunction (may cause negative inotropic effects) 3
  • However, can be used safely in heart failure patients when monitored appropriately 5, 6

Duration of IV Therapy

  • Maintenance infusion (0.5 mg/min) can continue for 2-3 weeks regardless of age, renal function, or LV function 1
  • Limited experience beyond 3 weeks of continuous IV therapy 1
  • Transition to oral when arrhythmia controlled (see transition protocol below) 1

Transition to Oral Amiodarone

After <1 week IV (720 mg/day maintenance): 1

  • 800-1600 mg PO daily 1

After 1-3 weeks IV: 1

  • 600-800 mg PO daily 1

After >3 weeks IV: 1

  • 400 mg PO daily 1

These recommendations based on 50% oral bioavailability 1

Critical Safety Warnings

Contraindications:

  • Severe sinus node dysfunction 2
  • Marked sinus bradycardia 2
  • Second- or third-degree AV block without pacemaker 2
  • Heart transplant recipients 2

Drug Interactions:

  • Do not combine with procainamide or other QT-prolonging drugs without expert consultation 2, 3
  • Numerous interactions due to effects on multiple ion channels 3
  • Extremely long half-life (IV: 9-36 days) causes delayed adverse effects and drug interactions 3

Infusion Rate Warning:

  • Never exceed 30 mg/min initial infusion rate 1
  • Faster rates have caused fatal hepatocellular necrosis and renal failure 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.